S-1 As Monotherapy or in Combination with Leucovorin As Second-Line Treatment in Gemcitabine-Refractory Advanced Pancreatic Cancer: a Randomized, Open-Label, Multicenter, Phase II Study.

Feijiao Ge,Nong Xu,Yuxian Bai,Yi Ba,Yanqiao Zhang,Fei Li,Huayan Xu,Ru Jia,Yan Wang,Li Lin,Jianming Xu

DOI: https://doi.org/10.1634/theoncologist.2014-0223

IF: 45.3

2014-01-01

Journal of Clinical Oncology

Abstract:BACKGROUND:In this study, we compared the efficacy and safety of the oral fluoropyrimidine S-1 as monotherapy or in combination with leucovorin as the second-line treatment for patients with metastatic pancreatic cancer whose disease had progressed on gemcitabine treatment.METHODS:The study was a randomized, open-label, controlled study. Patients randomly received S-1 or S-1 in combination with leucovorin (SL arm) in 21-day cycles. The primary endpoint was the 6-month survival rate.RESULTS:A total of 92 patients were randomized to S-1 (n = 47) and SL (n = 45). No statistically significant differences were observed between the two arms with regard to 6-month survival rates (40% vs. 49%), median overall survival (5.5 vs. 6.3 months), median progression-free survival (1.9 vs. 3.0 months), and overall response rate (4.7% vs. 8.3%). The rate of major grade 3-4 adverse events of digestive toxicity was significantly higher in the SL arm than in the S-1 arm.CONCLUSION:Compared with S-1, SL did not improve the survival of patients with metastatic pancreatic cancer who had failed to benefit from prior gemcitabine treatment, but SL had a higher adverse event rate.